Lapatinib Teva

Lapatinib, the active ingredient in Lapatinib Teva, is a tyrosine kinase inhibitor presented as an unknown strength/oral dosage form for oral use. It targets HER2‑positive metastatic breast cancer and HER2‑positive metastatic gastric or gastro‑oesophageal junction adenocarcinoma. GNH USA supplies Lapatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lapatinib acts on HER2‑driven tumor pathways and is used in advanced HER2‑positive cancers.

- HER2‑positive metastatic breast cancer: improves progression‑free survival when combined with other HER2‑targeted agents. - HER2‑positive metastatic gastric cancer: contributes to disease control in combination regimens. - HER2‑positive gastro‑oesophageal junction adenocarcinoma: used as part of multi‑drug therapy to delay tumor progression.

Lapatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhea: frequent loose stools. - Rash: skin irritation, often on the trunk. - Nausea: feeling of sickness. - Fatigue: reduced energy levels. - Stomatitis: inflammation of the mouth lining. - Elevated liver enzymes: increased ALT/AST.

Serious or Rare Side Effects: - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: clinically significant liver injury. - Interstitial lung disease: breathing difficulties and cough. - Severe diarrhea leading to dehydration. - Thromboembolic events: blood clot formation.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor key parameters.

- Cardiac assessment: baseline and periodic echocardiograms for patients with cardiac history. - Liver function: monitor ALT, AST, and bilirubin before and during treatment. - Dermatologic monitoring: watch for severe rash or skin reactions. - Gastrointestinal vigilance: assess for persistent diarrhea or dehydration. - Drug interactions: review concomitant medications that affect CYP3A4. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Lapatinib’s metabolism involves CYP3A4, making it susceptible to drug‑drug interactions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase toxicity risk.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may lower absorption; separate dosing by at least 2 hours. - Warfarin: may enhance anticoagulant effect; monitor INR. - Digoxin: potential increase in serum levels; observe for toxicity. - Simvastatin: increased risk of myopathy; consider dose adjustment. - Proton pump inhibitors: may modestly affect bioavailability.